Ladiratuzumab vedotin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Ladiratuzumab vedotin
- DrugBank Accession Number
- DB15409
- Background
Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Ladiratuzumab vedotin
- SGN-LIV1A
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ladiratuzumab vedotin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ladiratuzumab vedotin. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Ladiratuzumab vedotin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ladiratuzumab vedotin. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Ladiratuzumab vedotin. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- VM4G5D1A60
- CAS number
- 1629760-29-7
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Angiosarcoma / Breast Cancer / Breast Neoplasms / Breast Tumor / HER2/Neu-positive Breast Cancer / Hormone Receptor Negative Tumor / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Locally Advanced Breast Cancer (LABC) / Stage I Breast Cancer / Triple-Negative Breast Cancer 1 2 Terminated Treatment Adenocarcinomas of the Gastroesophageal Junction / Esophageal Squamous Cell Carcinoma (ESCC) / Gastric Adenocarcinoma / Melanoma / Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) / Prostate Cancer / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Non-small Cell Lung Cancer 1 1 Completed Treatment HER2 Mutations Breast Neoplasms / HER2 Positive Breast Neoplasms / Hormone Receptor Positive Breast Neoplasms / Triple-Negative Breast Neoplasm 1 1, 2 Active Not Recruiting Treatment Triple-Negative Breast Neoplasm 1 1, 2 Recruiting Treatment Breast Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 15:26 / Updated at February 21, 2021 18:55